GlaxoSmithKline has entered into a strategic alliance with Dong-A Pharmaceuticals Co., of South Korea, acquiring a 9.9 percent stake for GBP 73.9 M (USD 109.5 M). The move aims to beef up the commercial position of both companies in the emerging markets as pharmaceutical sales slow in the developed West.